# NK Cell Therapy for Malignant Solid Brain Tumors

> **NCT07552233** · NA · RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Malignant Solid Brain Tumors
- Glioblastoma (GBM)
- Glioblastoma Multiforme (GBM)
- Brain Metastasis
- Malignant Meningioma

## Interventions

- **DRUG:** Autologous NK cells

## Key facts

- **NCT ID:** NCT07552233
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-12
- **Final completion:** 2030-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07552233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07552233, "NK Cell Therapy for Malignant Solid Brain Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07552233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*